Swiss Consensus Statement: Recommendations for optimising re-treatment with MabThera® (rituximab) in rheumatoid arthritis

Rituximab is an effective treatment of rheumatoid arthritis (RA), which has been approved for the treatment of moderate to severe disease in patients with an inadequate response to anti-TNF therapies. Rituximab differs from other available biological agents for RA by way of its unique mode of acti...

Full description

Bibliographic Details
Main Authors: A Finckh, D Kyburz, B Möller, U Schmiedel, P Villiger, U Walker
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2010-07-01
Series:Swiss Medical Weekly
Subjects:
Online Access:https://www.smw.ch/index.php/smw/article/view/1150